New Alzheimer’s drug approved in the US

The decision drew criticism from experts who said that the development company had not proven that the drug slows down cognitive ability.

US regulators have granted conditional approval for the first new Alzheimer’s drug in nearly twenty years.

The Food and Drug Administration (FDA) has approved the antibody-based drug aducanumab, developed by Biogen, a biotech company.

The drug reduces the amyloid plaques that affect the brains of Alzheimer’s patients.

However, the approval drew sharp criticism from experts, who said that the company has not proven that the drug slows down serious cognitive decline in patients suffering from this disease. The FDA will require Biogen to continue testing the drug after its release and ultimately show that patients actually feel better.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Author: Steve Cowan
Graduated From Princeton University. He has been at the Free Press since October 2014. Previously worked as a regional entertainment editor.
Function: Chief-Editor

Spelling error report

The following text will be sent to our editors:

137 number 0.236462 time